Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …

The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

PURPOSE We report the clinical outcomes of a randomized trial comparing prophylactic
whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate …

Background STAMPEDE has previously reported that the use of upfront docetaxel improved
overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long …

Background Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising
prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that …

Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for
oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to …

Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …